The Latest Breaking News from Johnson & Johnson (

The Oak Park Democrat continues to accept campaign money from Johnson & Johnson, 1 of 4 companies paying $26 billion to settle suits accusing them of fueling the crisis. He’s not the only Illinois official doing so.

Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two years. But there is no question some big-name stocks performed better than others since the pandemic bottom.

The company cites commercial reasons and has blamed 'misinformation' over the safety of the product for its declining sales in the past.

Johnson & Johnson stock is hitting its lowest level since March. Here's where it's a steal of a deal.

BALTIMORE — The tally of wasted COVID-19 vaccine continues to climb at the troubled Emergent BioSolutions plant in East Baltimore and now exceeds a half billion doses, according to findings a congressional panel released Thursday on the manufacturer once central to the U.S. coronavirus pandemic response.

Walgreens helped fuel the opioid epidemic in San Francisco by shipping hundreds of thousands of "suspicious orders" of prescription drugs to its pharmacies, a federal judge ruled Wednesday.

"I believe we were late to the market and US vaccination was driven by what was available and shown to work," said Novavax CEO Stanley Erck.

Someone with a lot of money to spend has taken a bearish stance on Johnson & Johnson (NYSE:JNJ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Two Washington Post journalists say pharmaceutical companies collaborated with each other — and with lawyers and lobbyists — to create laws to protect the industry. Their new book is American Cartel.

Someone with a lot of money to spend has taken a bullish stance on Johnson & Johnson (NYSE:JNJ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Johnson & Johnson (NYSE: JNJ) released their financial report for the second quarter of 2022, this week, demonstrating strong growth and promising guidance for the rest of the year. Analysts seem to agree, as the consensus rating for JNJ is MODERATE BUY.